Literature DB >> 524066

Human natural killer cell activity is augmented by interferon via recruitment of 'pre-NK' cells.

E Saksela, T Timonen, K Cantell.   

Abstract

Contact with various cell-line targets increases the natural killer (NK) activity of human lymphocytes. Supernatants of such 20 h co-cultures augment the NK activity of virgin lymphocyte populations, and the augmenting factor penetrates 0.2 micrometer Millipore filters. The supernatants also contain interferon, and partially purified human leucocyte interferon increases NK activity when added to 20 h assays with 51Cr-labelled K-562 target cells. Potent anti-interferon antiserum added to the co-cultures inhibits the target-cell-induced augmentation phenomenon. Both the target-cell contact and interferon-induced augmentation affect a population of human lymphocytes, from which the 'mature' NK cells have been removed by adsorption-elution using fetal fibroblasts as adsorbents. The activity of 'mature' NK cells is not enhanced, and we conclude that the augmentation is mediated by recruitment of 'pre-NK' cells.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 524066     DOI: 10.1111/j.1365-3083.1979.tb01348.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  34 in total

Review 1.  Regulation of cell proliferation and differentiation by interferons.

Authors:  M J Clemens; M A McNurlan
Journal:  Biochem J       Date:  1985-03-01       Impact factor: 3.857

2.  Effects of interferons and interleukin 2 on natural killing of cytomegalovirus-infected fibroblasts.

Authors:  S Bandyopadhyay; D S Miller; M Matsumoto-Kobayashi; S C Clark; S E Starr
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

3.  Immunoregulatory dysfunctions in type I diabetes: natural and antibody-dependent cellular cytotoxic activities.

Authors:  M P Nair; E W Lewis; S A Schwartz
Journal:  J Clin Immunol       Date:  1986-09       Impact factor: 8.317

4.  Natural killer cells in viral arthritis.

Authors:  J G Aaskov; D A Dalglish; J J Harper; J F Douglas; M D Donaldson; P J Hertzog
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

5.  Application of a new method for detecting the phenotype of target binding cells.

Authors:  R A Lindemann; J A Jenkins; R A Figlin; S H Golub
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  Production of interferon by Theileria annulata- and T. parva-infected bovine lymphoid cell lines.

Authors:  J S Ahmed; P Wiegers; S Steuber; E Schein; R O Williams; D Dobbelaere
Journal:  Parasitol Res       Date:  1993       Impact factor: 2.289

7.  Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon.

Authors:  K Funa; G V Alm; L Rönnblom; K Oberg
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

8.  Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study.

Authors:  S Nikolaus; P Rutgeerts; R Fedorak; A H Steinhart; G E Wild; D Theuer; J Möhrle; S Schreiber
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

9.  Streptococcus pneumoniae cocultured with fibroblasts enhances both interferon production and cytotoxic activity by lymphocytes.

Authors:  D A Weigent; S Baron; G J Stanton
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

10.  Treatment of patients with transitional cell carcinoma of the urinary bladder with intravesical poly I: poly C effects on natural killer function.

Authors:  C Moroz; B Kupfer; A Lindner; M Many
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.